Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP547 for cholestatic pruritus in primary biliary cholangitis or primary sclerosing cholangitis
MOH_2022-12-21_012017Phase 2Not yet recruiting
- Sponsor
- Escient Pharmaceuticals
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cholestatic pruritus comparing EP547 with Placebo (2 arms). Primary endpoint: Safety and tolerability of EP547. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
EP547
03
Conditions
cholestatic pruritus
Beyond the preview
Go deeper on MOH_2022-12-21_012017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-21_012017.